TY - JOUR
T1 - Improvements in the degree of understanding the treatment guidelines for schizophrenia and major depressive disorder in a nationwide dissemination and implementation study
AU - Numata, Shusuke
AU - Nakataki, Masahito
AU - Hasegawa, Naomi
AU - Takaesu, Yoshikazu
AU - Takeshima, Masahiro
AU - Onitsuka, Toshiaki
AU - Nakamura, Toshinori
AU - Edagawa, Reon
AU - Edo, Hiroaki
AU - Miura, Kenichiro
AU - Matsumoto, Junya
AU - Yasui-Furukori, Norio
AU - Kishimoto, Taishiro
AU - Hori, Hikaru
AU - Tsuboi, Takashi
AU - Yasuda, Yuka
AU - Furihata, Ryuji
AU - Muraoka, Hiroyuki
AU - Ochi, Shinichiro
AU - Nagasawa, Tatsuya
AU - Kyou, Yoshitaka
AU - Murata, Atsunobu
AU - Katsumoto, Eiichi
AU - Ohi, Kazutaka
AU - Hishimoto, Akitoyo
AU - Inada, Ken
AU - Watanabe, Koichiro
AU - Hashimoto, Ryota
N1 - Funding Information:
This study was supported by the Japan Agency for Medical Research and Development (AMED) under Grant Number JP 18dk0307060, the AMED under Grant Number JP 19dk0307083, the Health and Labor Science Research Grants (H29-Seishin-Ippan-001, 19GC1201), the Japanese Society of Neuropsychopharmacology and the Japanese Society of Mood Disorders. The funders had no role in the study design, data collection and analyses, decision to publish, or preparation of the manuscript
Publisher Copyright:
© 2021 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Society of Neuropsychopharmacology
PY - 2021/6
Y1 - 2021/6
N2 - Background: To implement clinical practice guidelines (CPGs), it is necessary for psychiatrists to deepen their understanding of the CPGs. The Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE) project is a nationwide dissemination and implementation study of two sets of CPGs for schizophrenia and major depressive disorder (MDD). Methods: A total of 413 psychiatrists (n = 212 in 2016; n = 201 in 2017) learned the two CPGs in the education program of the EGUIDE project, and clinical knowledge of these CPGs was evaluated at baseline and after the programs. To improve the correct answer rate for clinical knowledge after the programs, we revised the lecture materials associated with items that had a low correct answer rate in 2016 and used the revised lecture materials with the CPGs in 2017. The rates of correct answers after the programs between the 2016 and 2017 groups were compared. Results: The correct answer rate of one item on the schizophrenia CPG and one item on the MDD CPG tended to be improved (S-D5 and D-C6) and that of one on the MDD CPG was significantly improved (D-D3, P = 0.0008) in the 2017 group compared to those in the 2016 group. Conclusions: We reported improvements in clinical knowledge of CPGs after the EGUIDE program in the 2017 group following revision of the lecture materials based on results from the 2016 group. These attempts to improve the degree of understanding of CPGs may facilitate the successful dissemination and implementation of psychiatric guidelines in everyday practice.
AB - Background: To implement clinical practice guidelines (CPGs), it is necessary for psychiatrists to deepen their understanding of the CPGs. The Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE) project is a nationwide dissemination and implementation study of two sets of CPGs for schizophrenia and major depressive disorder (MDD). Methods: A total of 413 psychiatrists (n = 212 in 2016; n = 201 in 2017) learned the two CPGs in the education program of the EGUIDE project, and clinical knowledge of these CPGs was evaluated at baseline and after the programs. To improve the correct answer rate for clinical knowledge after the programs, we revised the lecture materials associated with items that had a low correct answer rate in 2016 and used the revised lecture materials with the CPGs in 2017. The rates of correct answers after the programs between the 2016 and 2017 groups were compared. Results: The correct answer rate of one item on the schizophrenia CPG and one item on the MDD CPG tended to be improved (S-D5 and D-C6) and that of one on the MDD CPG was significantly improved (D-D3, P = 0.0008) in the 2017 group compared to those in the 2016 group. Conclusions: We reported improvements in clinical knowledge of CPGs after the EGUIDE program in the 2017 group following revision of the lecture materials based on results from the 2016 group. These attempts to improve the degree of understanding of CPGs may facilitate the successful dissemination and implementation of psychiatric guidelines in everyday practice.
UR - http://www.scopus.com/inward/record.url?scp=85102287312&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85102287312&partnerID=8YFLogxK
U2 - 10.1002/npr2.12173
DO - 10.1002/npr2.12173
M3 - Article
C2 - 33704931
AN - SCOPUS:85102287312
SN - 2574-173X
VL - 41
SP - 199
EP - 206
JO - Neuropsychopharmacology Reports
JF - Neuropsychopharmacology Reports
IS - 2
ER -